核 indd

397 48 会期 2015 7 11 会場 4 世話人 1. FDG-PET/CT CT 398 2. FDG-PET/CT 398 3. Change in thyroid gland perfusion after anti-vegf therapy studied by means of 15 O-H2O PET 399 4. 2014 Lugano 5-point scale FDG-PET 399 5. video 400 6. 3 400 7. 2 400 8. 99m Tc-ECD SPECT 401 9. 401 10. 99m Tc-DMSA 402 11. 123 I-MIBG SPECT/MRI 402 12. SPECT/CT 402 13. 18 F-FDG PET 2 403 14. PET FDG 403 15. ER FES-PET 2 404 16. FDG PET/CT T 404 17. FDG PET Neurolymphomatosis 1 404 18. 131 I 2 405 19. 405 20. PET 406 21. 406 特別講演 RI JA

398 48 一般 演題 1. FDG-PET/CT による尿路上皮癌の尿路外再発診断 : 診断用 CT との比較 3 1 PET 2 3 FDG FDG-PET/CT CT 3 83 55 16 12 69.7±10.6 66 17 gold standard PET/CT CT 67 TURBT BCG 30 27 10 28 26 2 PET/CT 100%=22/22 98.4%= 60/61 86.7%=13/15 98.5%= 67/68 93.8%=15/16 98.5%= 66/67 100%=8/8 100% =75/75 100%= 8/8 98.7%=74/75 100%=8/8 100%=75/75 100%=2/2 100%=81/81 CT (81.8%) (25.0%) (87.5%) (37.5%) (50%) PET/CT (p= 0.0026) PET/CT 97.4% (37/38) 93.3% (42/45) 95.2% (79/83) CT 86.8% (33/38) 93.3% (42/45) 90.4% (75/83) PET/CT 7 (8.4%) 3 2 1 PET/CT CT FDG-PET/CT CT 2. 骨悪性リンパ腫と線維性骨異形成における FDG- PET/CT 1 2 2 1 2 PET FDG-PET FDG-PET/CT 2006 1 2015 3 FDG-PET/CT 11 7 18 7 11 59 18 77 SUVmax 2 t EZR ROC AUC SUVmax 1.9 10.9 ±(SD) 5.1±2.7 26.6 ±(SD) 13.9±4.3 SUVmax 9.5 71.4% 85.7% AUC 0.816

48 399 PET FDG SUVmax SUVmax FDG-PET/CT SUVmax 3. Change in thyroid gland perfusion after anti- VEGF therapy studied by means of 15 O-H 2O PET 1 2 3 4 1 1 1 1,5 1 1 2 3 RI 4 5 Objectives: Normal capillaries of thyroid gland is known to regress after anti-vegf therapy in mice. The purpose of this study was to evaluate a change in thyroid gland perfusion before/after chemotherapy with anti-vegf agent bevacizumab (BEV) in humans using 15 O-H2O PET. Methods: Four patients with advanced adenocarcinoma of lung underwent a 10 min dynamic 15 O-H2O PET scan before and 1 2 days after administration of carboplatin (CBDCA)+paclitaxel+BEV or CBDCA+pemetrexed +BEV. Using nonlinear regression, 15 O-H2O thyroid gland time activity curves were fitted to the single-tissue compartment model using image derived input functions, which were determined using volumes of interest over ascending aorta. Results: Although median perfusion in the thyroid gland showed a decrease (from 0.99 to 0.63 ml/min/cm 3 ) within 2 days after administration of BEV, the perfusion change in the thyroid gland was not statistically significant. Conclusion: The perfusion in the thyroid gland did not change significantly after administration of BEV. 4. 悪性リンパ腫診断ガイドライン 2014 年改訂 Lugano 分類 :5-point scale を用いた FDG-PET 効果判定 2007 2014 Lugano FDG-avid FDG-PET gold standard FDG-PET 5-point scale score 1 BG score 2 score 3 score 4 score 5 CR score 1 3 PR score 4 5 SD score 4 5 PD score 4 5 FDG-PET BG ( 2 cm <2 cm) ( 1.5 cm <1.5 cm) 2014 Lugano 2014 Lugano FDG-PET 5-point scale

400 48 5. 小児核医学検査における video 注視の有用性 1 3 2 2 2 1 1 2 3 3 video video 6. レビー小体型認知症の診断に苦慮した認知症の 3 例 各種検査の比較 1 2 2 1 1 2 (DLB) (DAT) ezis SPECT DAT DLB MIBG DLB H/M FP-CIT DLB SBR DLB DAT SPECT MIBG FP-CIT 3 1 H/M 1.785 1.453 SBR 3.52 2 H/M 1.292 1.144 SBR 2.54 2 DLB 1 H/M 1.9792.158 SBR 4.63 MCI DLB MIBG FP-CIT 7. 長期アルコール依存患者における統計的画像解析を用いたアルツハイマー型認知症の鑑別の検討第 2 報 1 1 3 2 2 1 1 5 4 2 1 1 2 3 4 5 20% (ARD) ARD (DAT) DAT ARD ARD DAT SPECT ARD DAT SPECT 10 59.3 SPECT ECD ezis

48 401 6 ezis DAT 4 ARD DAT ezis 8. 99m Tc-ECD SPECT 検査の後方視的検討 1 1,2 1 1 2 99m Tc-ECD SPECT SISCOM (2009 version 1.0) 2010 4 1 2015 3 5 99m Tc-ECD SPECT 2 10 4 3 1 2.5 2 2 SPECT SPECT 99m Tc-ECD SPECT 99m Tc- ECD 5 SISCOM SPECT MRI 2 1) SISCOM 2) 1) 4 SISCOM 2) SISCOM 3 1 5 99m Tc-ECD SPECT SISCOM 9. 好酸球性膀胱炎の一例 2 MRI MRI FDG-PET/CT PET/CT FDG (SUVmax 7.96) TUR-BT 2 88

402 48 10. 小児慢性腎疾患における 99m Tc-DMSA 集積率の意義 2 2 2 1 2 CKD DMSA egfr CKD stage 2008 3 2010 6 DMSA CKD 35 17 0 132 16 17 2 GFR (egfr-cre) C GFR (egfr-cys) (n=35 n=28) CKD DMSA %DMSA %DMSA egfr-cre %DMSA egfr-cys CKD %DMSA 1: 20 2: 10 3: 3 4: 1 5: 1 %DMSA egfr-cre %DMSA egfr-cys r=0.80 r=0.84 CKD %DMSA ± 1: 39.6±5.8 2: 31.8±5.5 3: 15.8±13.1 4: 5.1±n.d. 5: 0±n.d. 1 3 %DMSA CKD DMSA CKD 11. 123 I-MIBG SPECT/MRI 融合像を用いた子宮内膜症診断の試み 2 2 1 1 2 123 I-metaiodobenzylguanidine (MIBG) SPECT MRI 4 2 A 2 B 123 I-MIBG SPECT 167 MBq 123 I-MIBG 15 3 6 MRI T2 SPECT A 2 1 15 3 6 B 2 123 I-MIBG SPECT MRI 12. SPECT/CT 併用アシアロシンチグラフィによる急性肝障害患者の病状評価 1 2 SPECT/CT

48 403 5 35 22 13 99m Tc-GSA 185 MBq 20 dynamic SPECT/ CT Planar LHL15 HH15 SPECT/CT SPECT SPECT HH15 SPECT SPECT ChE AFP LHL15 HH15 SPECT SPECT AFP (OR: 1.09, p=0.001) SPECT (OR: 3.72, p=0.002) SPECT/CT 13. 18 F-FDG PET 後期像で描出し得た浸潤性膀胱癌の 2 例 1 2 QOL PET PET 1 2 PET-CT 2 60 500 ml 120 14. PET 検診で発見された FDG 集積を伴う解離性大動脈瘤の一例 PET 64 2013 11 25 2 3 12 10 PET CRP HDL PET/CT Gemini-GXL FDG 336 MBq FDG-PET/CT CT 50 mm PET/CT FDG TBR 1.39 2.41 (Stanford A, Debakey II) + 1/3 PET FDG FDG

404 48 15. ER 陽性乳癌術後補助ホルモン療法後再発巣に対して FES-PET を行った 2 症例 2 2 2 2 1 2 18 F-16alpha- 17- ([ 18 F]FES) (ER) PET ER [ 18 F]FES-PET ER ER [ 18 F] FES 2 [ 18 F]FES [ 18 F]FDG 60 PET 4 1 FES FDG 1 FES FDG [ 18 F]FES-PET ER [ 18 F]FES [ 18 F]FDG PET 16. FDG PET/CT を施行した稀なセリアック病合併腸管症関連 T 細胞リンパ腫の一例 3 4 5 5 6 7 1 PET 2 3 4 5 6 7 60 5 IL-2R MALT PET/ CT SUVmax FDG 1 8.8 2 14.2 PET/CT 6 CD3(+) CD5(+) CD8(+) CD10( ) CD20( ) CD30( ) CD56( ) CD79a( ) EMA( ) CD3(+) CD20( ) CD79a( ) T T CD8(+) NK/T CD56( ) T T T 17. FDG PET で診断された Neurolymphomatosis の 1 例 Neurolymphomatosis (NL) 90% Non-Hodgkin lymphoma

48 405 MRI 40% 80% FDG-PET NL 100% PET NL 4 1 NL PET 18. 当院における 131 I 放射性ヨード残存甲状腺床破壊治療の成績 ( 第 2 報 ) 3 1 1 1.85 GBq 23 11 26 12 1.85 GBq 61 17 44 59.5 37 86 1 3 3 3 TSH (Tg) 1 3 131 I 3 Tg 2 ng/ml 61 55 (90.2%) 48 22 (45.8%) BMI T N TSH Tg TSH Tg TSH 3 Tg TSH 14 U Mann-Whitney U BMI Tg Tg Tg P =0.0065 6.35 95% 1.17 80.2 Tg P =0.03 1.30 95% 1.02 1.75 Tg Tg 19. 核医学画像への超解像の適用 1 2 3 4 4 4 4 4 1 2 3 4 4K UHD 8K UHD GMRF

406 48 20. 可搬型 PET 装置の初期使用経験 PET/MRI MRI PET (fxpet) fxpet fxpet MRI DOI-TOF fxpet MRI PET/MRI FDG DOTATOC PET/CT 20 =10 10 PET/CT fxpet MRI fxpet PET 15 MRI 1 axial FOV 15 cm 4 1 MRI T1 μ fxpet PET fxpet PET MRI MRI fxpet 29 PET fxpet (SUVmax, SUVpeak) R 2 =0.95, R 2 =0.91 PET MRI 21. 遠隔システムを用いた核医学診断の経験 25 26 6 1 0.5 50 on site